206 avsnitt
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education cancerGRACE
-
- Hälsa och motion
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
-
Management of Bispecific Antibodies Side Effects
Dr. Sridevi Rajeeve discusses possible side effects from bispecific antibodies, and how to manage them.
-
Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
-
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
Dr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)
-
Barriers to Biomarker Testing: Cost and Insurance
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
-
Barriers to Biomarker Testing: Ordering Tests
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC
-
The Adaura Trial: The Effect on EGFR+ Treatment
Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.